Data on other small tyrosine kinase inhibitors including BRAF inhibitor dabrafenib in patients with renal and liver dysfunction (NCT01907802) have not been reported (https://clinicaltrials.gov/ct2/show/study/NCT01907802). This evidence concerns the gene BRAF and Decreased liver function.